TY - JOUR
T1 - Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis
AU - Chiasakul, Thita
AU - Redd, Robert
AU - Patell, Rushad
AU - Khan, Adeel M.
AU - McCarthy, Ellen P.
AU - Neuberg, Donna
AU - Zwicker, Jeffrey I.
N1 - Publisher Copyright:
© 2021 International Society on Thrombosis and Haemostasis.
PY - 2021/11
Y1 - 2021/11
N2 - Background: When compared with warfarin, low-molecular-weight heparin (LMWH) reduces the incidence of recurrent venous thromboembolism (VTE) in cancer. However, a survival benefit of LMWH over warfarin for the treatment of cancer-associated VTE has not been established. Methods: Using the Surveillance, Epidemiology and End Results and Medicare linked database from 2007 through 2016, we identified Medicare beneficiaries (aged ≥66 years) who were: (1) diagnosed with primary gastric, colorectal, pancreatic, lung, ovarian, or brain cancer; (2) diagnosed with cancer-associated VTE; and (3) prescribed LMWH or warfarin within 30 days. The primary outcome was overall survival (OS). Patients were matched 1:1 using exact matching for cancer stage and propensity score matching for cancer diagnosis, age, year of VTE, and time from cancer diagnosis to index VTE. Cox proportional-hazards regression was performed to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). Results: A total of 9706 patients were included. Warfarin was associated with a significant improvement in OS compared with LMWH (median OS, 9.8 months [95% CI, 9.1–10.4] vs. 7.2 months [95% CI, 6.8–7.8]; HR, 0.86; 95% CI 0.83–0.90; p <.001). The survival advantage was most pronounced in pancreatic (HR 0.82 [95% CI, 0.74–0.90], p <.001) and gastric cancers (HR 0.82 [95% CI, 0.68–0.98], p =.03). The observed differences in survival were consistent across subgroups including cancer stage, age, comorbidity burden, and year of VTE. Conclusions: In this population-based study, warfarin was associated with improved OS compared with LMWH for the treatment of cancer-associated VTE.
AB - Background: When compared with warfarin, low-molecular-weight heparin (LMWH) reduces the incidence of recurrent venous thromboembolism (VTE) in cancer. However, a survival benefit of LMWH over warfarin for the treatment of cancer-associated VTE has not been established. Methods: Using the Surveillance, Epidemiology and End Results and Medicare linked database from 2007 through 2016, we identified Medicare beneficiaries (aged ≥66 years) who were: (1) diagnosed with primary gastric, colorectal, pancreatic, lung, ovarian, or brain cancer; (2) diagnosed with cancer-associated VTE; and (3) prescribed LMWH or warfarin within 30 days. The primary outcome was overall survival (OS). Patients were matched 1:1 using exact matching for cancer stage and propensity score matching for cancer diagnosis, age, year of VTE, and time from cancer diagnosis to index VTE. Cox proportional-hazards regression was performed to estimate hazard ratios (HR) and 95% confidence intervals (95% CI). Results: A total of 9706 patients were included. Warfarin was associated with a significant improvement in OS compared with LMWH (median OS, 9.8 months [95% CI, 9.1–10.4] vs. 7.2 months [95% CI, 6.8–7.8]; HR, 0.86; 95% CI 0.83–0.90; p <.001). The survival advantage was most pronounced in pancreatic (HR 0.82 [95% CI, 0.74–0.90], p <.001) and gastric cancers (HR 0.82 [95% CI, 0.68–0.98], p =.03). The observed differences in survival were consistent across subgroups including cancer stage, age, comorbidity burden, and year of VTE. Conclusions: In this population-based study, warfarin was associated with improved OS compared with LMWH for the treatment of cancer-associated VTE.
KW - anticoagulation
KW - cancer-associated thrombosis
KW - low-molecular-weight heparin
KW - venous thromboembolism
KW - warfarin
UR - http://www.scopus.com/inward/record.url?scp=85115202918&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115202918&partnerID=8YFLogxK
U2 - 10.1111/jth.15519
DO - 10.1111/jth.15519
M3 - Article
C2 - 34490999
AN - SCOPUS:85115202918
SN - 1538-7933
VL - 19
SP - 2825
EP - 2834
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
IS - 11
ER -